Net profit rebounded to CHF 451mn in Q2 2026, with NAV outperforming the Nasdaq Biotech Index. Portfolio diversification and strategic M&A activity drove results, while a disciplined capital allocation framework was reinforced by a 3-5% dividend yield and share buybacks.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.